228 results on '"Guthrie, Spencer"'
Search Results
2. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
3. Automatic quantification of AL and ATTR amyloidosis disease burden using 124I-evuzamitide, a novel radiotracer
4. The value of AI for enhancing suspicion of cardiac amyloidosis using electrocardiography and echocardiography: A narrative review
5. Repeat Imaging Of Patients With AL And ATTR Amyloidosis, By 124I-AT-01 PET/CT Imaging, Reveals Dynamic Organ-Specific Changes In Amyloid Load Over Time
6. The Peptide Fusion Immunoglobulin, AT-02, Exhibits Highly Potent Pan-Amyloid Reactivity And Immunomodulation
7. Longitudinal PET/CT imaging with iodine ( 124 I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis
8. The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
9. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
10. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
11. Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center
12. Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study.
13. Light Chain (AL) Amyloidosis: The Journey to Diagnosis
14. Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide 124I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET/CT Imaging
15. A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
16. Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide 124 I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET/CT Imaging.
17. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
18. DETECTION OF CARDIAC AMYLOIDOSIS IN PATIENTS WITH SYSTEMIC AL AND ATTR AMYLOIDOSIS USING IODINE EVUZAMITIDE PET/CT IMAGING AND THE CORRELATION WITH SERUM NT-PROBNP
19. Longitudinal PET/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis.
20. Detection of Systemic AL Amyloidosis By 124I-p5+14 PET/CT Imaging - Providing the Complete Picture for Diagnosis
21. Pre-Clinical Characterization of a Novel Fusion Protein (AT-03), with Pan-Amyloid Binding and Removal
22. Systemic Amyloid Response in Patients with AL Amyloidosis Assessed By Serial Iodine ( 124I) Evuzamitide PET/CT Imaging
23. Operationalization of Global Alzheimer’s Disease Trials
24. List of Contributors
25. Detection of Systemic AL Amyloidosis and Differentiation of AL from Attr Using 124I-p5+14 PET Imaging
26. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis
27. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
28. Improvement in Quality of Life in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Cardiomyopathy Treated with Inotersen in the Phase 3 Study NEURO-TTR
29. Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
30. A Study of Environmental and Track Factors that Contribute to Abrasion Damage of Concrete Ties
31. Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis
32. Characterizing the Journey to Diagnosis for Patients with Transthyretin Amyloidosis and Accompanying Congestive Heart Failure
33. Phase 1 Investigation of a Ligand-Conjugated Antisense Oligonucleotide with Increased Potency for the Treatment of Transthyretin Amyloidosis
34. Amyloidosis Research Consortium Cardiac Amyloidosis Survey: Results from Patients with AL and ATTR Amyloidosis and Their Caregivers
35. Burden of hereditary transthyretin amyloidosis on quality of life
36. Long-Term Efficacy and Safety of Inotersen for Hereditary Transthyretin Amyloidosis: NEURO-TTR Open-Label Extension 2-Year Update (S27.008)
37. Quality of Life (QOL) in Patients with Transthyretin Amyloidosis Accompanied by Peripheral Neuropathy (PN) (P3.9-062)
38. Responsiveness of Neuropathy Symptom and Change (NSC) Score Components in Inotersen Treatment of Hereditary Transthyretin Amyloidosis Polyneuropathy (P3.9-060)
39. The Impact of Hereditary Transthyretin Amyloidosis (hATTR) on Work: The Patients’ Perspectives (P3.9-061)
40. Impact de l’inotersen sur des sous-groupes de patients atteints d’amylose à TTR héréditaire : résultats d’un essai contre placebo en double aveugle
41. Étude de prolongation ouverte de l’essai NEURO-TTR chez les patients atteints d’amylose héréditaire à transthyrétine
42. CLINICAL OUTCOME ASSESSMENT SCORES FOR PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH OR WITHOUT ACCOMPANYING CARDIOMYOPATHY OR CONGESTIVE HEART FAILURE
43. SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
44. Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis
45. Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial
46. Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial
47. Cardiac biomarkers and health‐related quality of life in patients with light chain ( AL ) amyloidosis
48. Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data
49. Epidemiology of AL amyloidosis: a real-world study using US claims data
50. Environmental and Track Factors That Contribute to Abrasion Damage
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.